Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

SPDR® S&P Biotech ETF (XBI)

Delayed Data
As of Aug 27
 +5.57 / +2.54%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.


1 month-14.46% 3 years+36.08%
3 months-5.95% 5 years+33.40%
1 year+35.54% Since inception+17.21%
Data through 08/27/2015

Quote Details

Previous close$218.99
Open day’s range219.25 – 225.80
Net asset value (NAV)218.67 (08/26/2015)
Daily volume2,645,801
Average volume (3 months)1,453,677
Data as of 08/27/2015

Peer Comparisonvs. Health ETFs

Performance 5-yr return+33.40%+26.72%
Expense Gross exp ratio0.35%0.46%
Risk 5 year sharpe ratio1.381.76
Net assets$2.9B$2.2B
Average market cap$2.4B$38.7B
Average P/E--26.0
Dividend / Share--0.21%


XLV Health Care Select Sector SPDR® Fund
VHT Vanguard Health Care Index Fund ETF Shar...
RYH Guggenheim S&P 500® Equal Weight Health...


Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ANAC Anacor Pharmaceuticals Inc1.98%
RDUS Radius Health Inc1.51%
EXEL Exelixis Inc1.48%
PRTA Prothena Corporation PLC1.34%
XON Intrexon Corp1.34%
ZIOP ZIOPHARM Oncology Inc1.31%
DVAX Dynavax Technologies Corp1.29%
OPHT Ophthotech Corp1.28%
RARE Ultragenyx Pharmaceutical Inc1.26%
KYTH KYTHERA Biopharmaceuticals Inc1.26%

Partner Offers